In addition to using gemcitabine and the natural killer cells that are TGF-β imprinted, we also are combining an anti-GD2 antibody called naxitamab that's provided by Y-mAbs. Naxitamab, as I said, is ...
New study successfully made CTC-derived organoids from breast cancer patients' blood samples to investigate cell survival and ...
Mersana shares Phase 1 data on Emi-Le for TNBC and details FDA's Fast Track status for XMT-1660 in advanced HER2-low breast ...
Cancer researchers at the University of Leicester have developed a technique that could predict how well some breast cancer ...
Nearly half of the most popular protein powders on the market tested positive for higher-than-safe levels of heavy metals, ...
Mersana Therapeutics (MRSN) stock hits a 52-week low in reaction to early clinical results for its cancer drug Emi-Le in ...
For female patients aged at least 66 years, odds of prevalent CVD up with locally advanced and metastatic disease.
Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug ...
TrialTranslator uses machine learning to assess cancer RCT generalizability, revealing survival gaps for high-risk patients ...
Intensity Therapeutics, Inc. ("Intensity" or the "Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based ...
Arvinas (ARVN) announced updated guidance for the planned first- and second-line combination clinical trials for vepdegestrant in patients with ...
Patients with HR+/HER2− metastatic breast cancer without previous systemic therapy were randomly assigned to receive either ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback